摘要
目的探讨依达拉奉联合尼莫地平治疗蛛网膜下腔出血的临床疗效、不良反应及其对患者血清C-反应蛋白(CRP)、S100蛋白水平的影响。方法选取2014年5月至2015年5月我院收治的蛛网膜下腔出血患者76例,随机分成对照组与观察组,每组各38例。对照组给予尼莫地平治疗,而观察组在对照组的基础上加用依达拉奉,两组疗程均为两周。观察并记录两组患者治疗一疗程后的临床疗效,治疗前及治疗后3d、7d、14d患者血清CRP与S100的水平,治疗期间不良反应的发生情况及随访3个月后的预后情况。结果观察组的治疗总有效率为92.1%,显著高于对照组71.1%,差异有统计学意义(P<0.05);治疗后两组血清S100水平及对照组血清CRP均呈上升再下降的趋势,均于治疗第7d上升至峰值,而观察组CRP一直呈降低状态,其中观察组治疗后3d、7d、14d的CRP及S100水平均显著低于同期对照组,差异有统计学意义(P<0.05);而两组不良反应情况组间比较差异无统计学意义(P>0.05);同时预后情况比较观察组也显著优于对照组,差异有统计学意义(P<0.05)。结论依达拉奉联合尼莫地平治疗蛛网膜下腔出血临床疗效显著,同时能有效抑制患者血清CRP及S100水平的上升,并且安全可靠、预后较好,值得临床推广应用。
Objective To investigate the clinical efficacy of edaravone combined with nimodipine nimodipine in the treatment of subarachnoid hemorrhage,adverse reactions and the levels of serum C reactive protein（ CRP）and S100 protein. Methods 76 cases of subarachnoid hemorrhage were randomly divided into the control group and the observation group,38 cases in each group. The control group was given nimodipine treatment,while the observation group was treated with edaravone on the basis of the control group. The courses of treatment in the two groups were two weeks. The serum CRP and S100 levels before treatment and 3,7,and 14 days after treatment in both group were detected. The adverse reactions during treatment and 3 months follow-up were recorded. Results The total treatment efficiency in observation group of 92. 1% was significantly higher than that of the control group of 71. 1%（ P〈0. 05）. After the treatment,the serum S100 levels in both group and the serum CRP levels in control group showed a rise and then decline trend,with peak on 7 days after treatment.While the serum CRP and S100 levels in observation group on 3,7 and 14 days after treatment were significantly lower than that of control group at the same period（ P〈0. 05）. There was no significantly difference on adverse reactions between two groups（ P〉0. 05）. The prognosis of the observation group was significantly better than that of control group（ P〈0. 05）. Conclusion The edaravone combined with nimodipine in the treatment of subarachnoid hemorrhage have significant clinical curative effect,and could effectively inhibit the rise of serum levels of CRP and S100. It is safe and reliable with good prognosis,and worth for wildly clinical application.
出处
《标记免疫分析与临床》
CAS
2016年第4期385-388,共4页
Labeled Immunoassays and Clinical Medicine
基金
国家自然科学基金(81401067)
